News for Sarepta Therapeutics, Inc. (SRPT)

On February 28, 2025, Casdin Capital, LLC (Trades, Portfolio) executed a significant stock transaction involving Standard BioTools Inc. The firm added 9,609,638

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ETCompany ParticipantsMary Jenkins - Associate Director,...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter a

Sarepta Therapeutics (SRPT) announces Q4 earnings on Feb 26. Analysts predict EPS growth of 151.2% & revenue up 59%.

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at where Sarepta Therapeutics, Inc.

The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

On December 31, 2024, Casdin Capital, LLC (Trades, Portfolio), a prominent investment firm, expanded its holdings in Neurogene Inc by acquiring an additional 27

Significant Transaction by Capital International Investors (Trades, Portfolio) On December 31, 2024, Capital International Investors (Trades, Portfolio) execute

On December 31, 2024, Altium Capital Management LLC (Trades, Portfolio) executed a notable transaction by acquiring 193,877 shares of PMGC Holdings Inc, trading

Summary Sarepta Therapeutics Inc (SRPT), a leader in precision genetic medicine for rare diseases, announced on February 14, 2025, the successful closure of a $

Summary Sarepta Therapeutics Inc (SRPT), a leader in precision genetic medicine for rare diseases, has announced that it will release its fourth quarter and ful

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial r

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this month, are Eli Lilly (NYSE: LLY) and Sarepta Therapeutics (NASDAQ: SRPT). Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress. The company's breakthroughs are paying off.

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Sarepta Therapeutics, Inc.

We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on SRPT.

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% gain by 2025. Read the full stock report here on Seeking Alpha.

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs said in a report.